Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at Costco misses analysts’ estimates, and EchoStar rises on reports its Dish subsidiary is in merger talks with DirecTV.
Shares of Cassava Sciences (SAVA) are falling after reaching a settlement with US securities regulators. This comes after the pharmaceutical company was charged for misleading claims about an Alzheimer's clinical trial. Market Domination Hosts Julie Hyman and Josh Lipton report more on the story. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Shares of Cassava Sciences, Inc (NASDAQ:SAVA) dropped 11.5% in pre-open trade on Friday following the company's statement that it has reached a $40 million settlement with the U.S. Securities and Exchange Commission (SEC) over negligence-based disclosure charges. Cassava Sciences, Inc. settled the charges with the SEC, agreeing to pay a $40 million penalty, without admitting or denying the SEC’s allegations. Cassava stated that it fully cooperated with the SEC and has since implemented remedial measures.